Nigam MAschebrook-Kilfoy BShikanov S. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol 2015;33:623–631.
Verdecchia AFrancisci SBrenner H. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007;8:784–796.
Capocaccia RGatta GDal Maso L. Life expectancy of colon, breast, and testicular cancer patients: an analysis of US-SEER population-based data. Ann Oncol 2015;26:1263–1268.
Travis LBBeard CAllan JM. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010;102:1114–1130.
Araujo ABEsche GRKupelian V. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241–4247.
Kaufman JMVermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833–876.
Harman SMMetter EJTobin JD. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001;86:724–731.
Feldman HALongcope CDerby CA. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589–598.
Isidori AMGiannetta EGreco EA. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005;63:280–293.
Hildreth KLBarry DWMoreau KL. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab 2013;98:1891–1900.
Ohlsson CWallaschofski HLunetta KL. Genetic determinants of serum testosterone concentrations in men. PLoS Genet 2011;7:e1002313.
De Groot LJChrousos GDungan K. Testicular cancer pathogenesis, diagnosis and endocrine aspects. In: Feingold KRAnawalt BBoyce A eds. Endotext [internet]. South Dartmouth, MA: MDText.com, Inc.; 2000.
Skakkebæk NERajpert-De Meyts EMain KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 2001;16:972–978.
Rajpert-De Meyts E. Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update 2006;12:303–323.
Fung CSesso HDWilliams AM. Multi-institutional assessment of adverse health outcomes among North American testicular cancer survivors after modern cisplatin-based chemotherapy. J Clin Oncol 2017;35:1211–1222.
Kerns SLFung CMonahan PO. Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study. J Clin Oncol 2018;36:1505–1512.
Zaid MAGathirua-Mwangi WGFung C. Clinical and genetic risk factors for adverse metabolic outcomes in North American testicular cancer survivors. J Natl Compr Canc Netw 2018;16:257–265.
Taylor HLJacobs DR JrSchucker B. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis 1978;31:741–755.
Chasan-Taber SRimm EBStampfer MJ. Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 1996;7:81–86.
Ainsworth BEHaskell WLHerrmann SD. 2011 Compendium of Physical Activities: a second update of codes and MET values. Med Sci Sports Exerc 2011;43:1575–1581.
Desroches BKohn TPWelliver C. Testosterone therapy in the new era of Food and Drug Administration oversight. Transl Androl Urol 2016;5:207–212.
Wheeler HEGamazon ERFrisina R. Variants in WFS1 and other Mendelian deafness genes are associated with cisplatin-associated ototoxicity. Clin Cancer Res 2017;23:3325–3333.
Howie BFuchsberger CStephens M. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012;44:955–959.
Barrett-Connor EKhaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988;78:539–545.
Khaw KTDowsett MFolkerd E. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007;116:2694–2701.
- Search Google Scholar
- Export Citation
)| false . , Khaw KT , Dowsett M , Folkerd E Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. 2007; 116: 2694– 2701. 18040028 10.1161/CIRCULATIONAHA.107.719005
Kupelian VHayes FJLink CL. Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J Clin Endocrinol Metab 2008;93:3403–3410.
Haring RVölzke HSteveling A. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010;31:1494–1501.
Li CFord ESLi B. Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care 2010;33:1618–1624.
Nuver JSmit AJWolffenbuttel BH. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005;23:3718–3725.
Wethal TKjekshus JRøislien J. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv 2007;1:8–16.
de Haas ECAltena RBoezen HM. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 2013;24:749–755.
Willemse PMBurggraaf JHamdy NA. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors [published correction appears in Br J Cancer 2013;109:295–296]. Br J Cancer 2013;109:60–67.
- Search Google Scholar
- Export Citation
)| false . , Willemse PM , Burggraaf J , Hamdy NA Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors [published correction appears in Br J Cancer 2013;109:295–296]. 2013; 109: 60– 67. 10.1038/bjc.2013.226
Haugnes HSAass NFosså SD. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007;18:241–248.
Fung CFossa SDMilano MT. Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 2015;33:3105–3115.
Haugnes HSWethal TAass N. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010;28:4649–4657.
Huddart RANorman AShahidi M. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513–1523.
Meinardi MTGietema JAvan der Graaf WT. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725–1732.
van den Belt-Dusebout AWde Wit RGietema JA. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25:4370–4378.
Dolan MEEl Charif OWheeler HE. Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer. Clin Cancer Res 2017;23:5757–5768.
Gerl AMühlbayer DHansmann G. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 2001;91:1297–1303.
Isaksson SBogefors KStåhl O. High risk of hypogonadism in young male cancer survivors. Clin Endocrinol (Oxf) 2018;88:432–441.
Ferlin ABogatcheva NVGianesello L. Insulin-like factor 3 gene mutations in testicular dysgenesis syndrome: clinical and functional characterization. Mol Hum Reprod 2006;12:401–406.
Xing JSBai ZM. Is testicular dysgenesis syndrome a genetic, endocrine, or environmental disease, or an unexplained reproductive disorder? Life Sci 2018;194:120–129.
Foresta CFerlin A. Role of INSL3 and LGR8 in cryptorchidism and testicular functions. Reprod Biomed Online 2004;9:294–298.
Basaria SCoviello ADTravison TG. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109–122.
Srinivas-Shankar URoberts SAConnolly MJ. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010;95:639–650.
- Search Google Scholar
- Export Citation
)| false . , Srinivas-Shankar U , Roberts SA , Connolly MJ Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. 2010; 95: 639– 650. 10.1210/jc.2009-1251
Budoff MJEllenberg SSLewis CE. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA 2017;317:708–716.
Bhasin SCunningham GRHayes FJ. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–2559.
Postma TJAaronson NKHeimans JJ. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005;41:1135–1139.
Oldenburg JFosså SDDahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res 2006;15:791–800.
Ventry IMWeinstein BE. The hearing handicap inventory for the elderly: a new tool. Ear Hear 1982;3:128–134.